- 🇸🇦 Saudi Stock Market
- 🇺🇸 USA Stock Market
Vertex Pharmaceuticals Incorporated, a biotechnology company, focuses on developing and selling therapies for cystic fibrosis (CF). The company offers various treatments such as TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO for different age groups of CF patients. Additionally, the company’s pipeline includes VX-522, VX-548, Exa-cel, inaxaplin, Type 1 Diabetes, VX-970, and cancer treatments. Vertex Pharmaceuticals Incorporated, established in 1989, is based in Boston, Massachusetts.
VRTX —  NASDAQ —
Current RSI of this stock is 63.94, which indicates the strength of buyers.
Increasing ADX value above 20, indicated the strength of the trend, thereby uptrending ADX confirms the bullish or bearish supportive decisions. Along with the rising ADX, and the +DI is above (or crossing) -DI, indicates the long trades should be favoured.
The short length exponential moving average (10 EMA) has crossed the long length exponential moving average (20 EMA) from the below, generates bullish signal. Last day’s candle has closed above all these moving averages. This suggests buyers are taking interest in this stock.
Based on our stock trading advice in United States, Vertex Pharmaceuticals stock price target will be USD 500 - USD 505 in the next 12-14 trading sessions.
Arijit Banerjee CMT CFTe is a seasoned expert in the financial industry, boasting decades of experience in trading, investment, and wealth management. As the founder and chief strategist of Naranj Capital, he’s built a reputation for providing insightful research analysis to guide investment decisions.
Arijit’s credentials are impressive, holding both the Chartered Market Technician (CMT) and Certified Financial Technician (CFTe) designations. These certifications demonstrate his expertise in technical analysis and financial markets.
Through Naranj Capital, Arijit shares his market insights and research analysis, offering actionable advice for investors. His work is featured on platforms like TradingView, where he publishes detailed analysis and recommendations.
If you’re interested in learning more about Arijit’s work or Naranj Capital’s services, you can reach out to them directly through their website
